BMN 110

DRUG7 trials

Sponsors

BioMarin Pharmaceutical

Conditions

MPS IV AMPS IVAMorquio A SyndromeMucopolysaccharidosis IVAMucopolysaccharidosis IVA (Morquio A Syndrome)

Phase 1

A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA

CompletedNCT00884949

BioMarin PharmaceuticalMPS IV A

Start: 2009-04-30End: 2011-03-31Updated: 2014-06-30

A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

TerminatedNCT01242111

BioMarin PharmaceuticalMorquio A Syndrome, MPS IV A, Mucopolysaccharidosis IVA

Start: 2010-11-30End: 2014-07-31Updated: 2015-09-30

Phase 2

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

CompletedNCT01515956

BioMarin PharmaceuticalMorquio A Syndrome, MPS IVA, Mucopolysaccharidosis IVA

Start: 2011-10-31End: 2016-02-29Updated: 2017-08-10

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

TerminatedNCT01609062

BioMarin PharmaceuticalMorquio A Syndrome, MPS IVA, Mucopolysaccharidosis IVA

Start: 2012-04-30End: 2014-11-30Updated: 2016-02-01

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

TerminatedNCT01697319

BioMarin PharmaceuticalMorquio A Syndrome, MPS IVA, Mucopolysaccharidosis IVA

Start: 2012-08-31End: 2014-10-31Updated: 2016-01-12

Phase 3

BMN 110 Phase 3B in Australian Patients

CompletedNCT01966029

BioMarin PharmaceuticalMucopolysaccharidosis IVA (Morquio A Syndrome)

Start: 2013-07-31End: 2016-12-31Updated: 2019-09-26

Unknown Phase

BMN 110 US Expanded Access Program

BioMarin PharmaceuticalMorquio A Syndrome, MPS IVA, Mucopolysaccharidosis IVA

Updated: 2014-04-02

Related Papers

Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment

Molecular Genetics and Metabolism2018-02-1925 citations

Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa.

2017-11-214 citations